News from novo nordisk inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 24, 2015, 09:00 ET

New Novo Nordisk Data Demonstrate Caregiver Burden and Prevalence of Pain in People Living With Hemophilia

Today, Novo Nordisk presented new data detailing the impact hemophilia has on both caregivers and those living with the disease. Results from 2...

Jun 24, 2015, 07:30 ET

In a Phase 3 Trial, Novoeight®(Antihemophilic Factor [Recombinant]) Provided Long-term Efficacy and Safety in the Prophylaxis and Treatment of Bleeds in People with Hemophilia A

Today, at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress, Novo Nordisk announced the latest interim data from the...

Jun 23, 2015, 13:55 ET
Novo Nordisk, Inc.

Great Place to Work® and Fortune Name Novo Nordisk as One of the 100 Best Workplaces for Millennials in the US

 In just 10 years, millennials will make up 75 percent of the workforce. To compete for top talent and ensure their long-term success,...

Jun 07, 2015, 08:00 ET

New IDegLira Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change, and Lower Rate of Hypoglycaemia Versus Insulin Glargine

- 166-OR For medical and consumer media in the US only  New phase 3b findings showed adults with type 2 diabetes treated with IDegLira, the...

Jun 06, 2015, 10:00 ET

New Study With Victoza® (Liraglutide [rDNA Origin] Injection) Showed Improvements in Blood Glucose Control in Adults With Type 2 Diabetes Who Fasted During Ramadan

Only for US media Abstract #1121-P New findings showed that adults with type 2 diabetes treated with Victoza® (liraglutide [rDNA origin]...

May 15, 2015, 12:10 ET

New analysis of data in adults with obesity or who are overweight with weight-related comorbidities showed early response to Saxenda® (liraglutide [rDNA origin] injection) predicted greater weight loss

 Today, new data from the phase 3a SCALE™ Obesity and Pre-diabetes trial were presented at the 24th Annual Scientific and Clinical...

Apr 22, 2015, 09:00 ET
Saxenda(R) (liraglutide [rDNA origin] injection) logo. Please see full Prescribing Information, including Boxed Warning, for Saxenda(R) at Saxenda.com

Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States

Novo Nordisk today announced that Saxenda® (liraglutide [rDNA origin] injection) is now available in the United States. Saxenda® is the...

Apr 17, 2015, 09:00 ET

Novo Nordisk Celebrates World Hemophilia Day and Shares New Support Programs, Including HeroPath™ and Career Counseling

 Novo Nordisk is proud to celebrate World Hemophilia Day, which aims to raise awareness of the disease and other inherited bleeding disorders....

Apr 14, 2015, 03:00 ET
Novo Nordisk Logo

Novo Nordisk Extends Programme for Children With Diabetes in Developing Countries

Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to...

Mar 26, 2015, 12:47 ET

Novo Nordisk to Launch Novoeight® in the United States for People With Hemophilia A

 Novo Nordisk today announced the company will launch Novoeight® (Antihemophilic Factor [Recombinant]) in the United States for people...

Mar 07, 2015, 16:00 ET
Mar 05, 2015, 10:00 ET
Novo Nordisk, Inc.

Novo Nordisk Named on the 2015 FORTUNE 100 Best Companies to Work For® List for Seventh Consecutive Year

 Novo Nordisk has ranked 66 on the FORTUNE "100 Best Companies to Work For®" list, marking the seventh consecutive year Novo Nordisk has...

Jan 26, 2015, 19:40 ET
Novo Nordisk, Inc.

Novo Nordisk Receives FDA Approval for Norditropin® FlexPro® 30 mg/3.0 mL for Patients with Growth Hormone Disorders

 Novo Nordisk announced today the U.S. Food and Drug Administration (FDA) approval of Norditropin® (somatropin [rDNA origin] injection)...

Dec 24, 2014, 17:41 ET
Novo Nordisk receives FDA approval for Saxenda(R) (liraglutide [rDNA origin] injection) for chronic weight management

Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide...

Dec 12, 2014, 09:00 ET

Novo Nordisk and Chip Ganassi Racing Teams Announce Multi-Year Sponsorship Agreement for Verizon IndyCar Series

 Novo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams (CGRT), today announced a multi-year extension of their...

Dec 10, 2014, 10:00 ET
Novo Nordisk, Inc.

Novo Nordisk Launches Community Health Collaborative™ Aimed At Improving Urban Health In New Jersey

 Novo Nordisk today announced the launch of the Community Health Collaborative™, a new initiative to support and expand healthy lifestyle...

Dec 07, 2014, 12:00 ET

Novoeight® Phase 3 Data Show Reduction in Annualised Bleeding Rate Over Time in People With Haemophilia A

Today, Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate...

Dec 01, 2014, 08:55 ET

Novo Nordisk to Present Hemophilia Portfolio and Pipeline Data at 56th American Society of Hematology Meeting

 Novo Nordisk will unveil 11 abstracts containing safety and efficacy data from its hemophilia portfolio and pipeline at the 56th Annual...

Nov 14, 2014, 02:00 ET
Novo Nordisk Logo

Tianjin og Shanghai tilslutter sig Cities Changing Diabetes på Verdensdiabetesdagen

I dag, på Verdensdiabetesdagen, tilslutter de to kinesiske storbyer Tianjin og Shanghai sig initiativet Cities Changing Diabetes, der er et...

Nov 14, 2014, 02:00 ET
Novo Nordisk Logo

Tianjin and Shanghai Join Cities Changing Diabetes on World Diabetes Day

Today, on World Diabetes Day, the Chinese cities of Tianjin and Shanghai join the Cities Changing Diabetes initiative and the global fight...